Recent advances in protein prenyltransferases: Substrate identification, regulation, and disease interventions

Current Opinion in Chemical Biology

Volumn 16, Issue 5-6, 2012, Pages 544-552

  Zverina, Elaina A ^a   Lamphear, Corissa L ^b   Wright, Elia N ^b   Fierke, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANNEXIN; DIMETHYLALLYLTRANSFERASE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LAMIN B; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PHYTOENE SYNTHASE; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE; RAB PROTEIN; RAB7 PROTEIN; SULFIDE; TEMOZOLOMIDE; THIOL ESTER HYDROLASE; TIPIFARNIB; ZOLEDRONIC ACID;

APOPTOSIS; ASTROCYTOMA; BACTERIAL INFECTION; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL DEATH; CELL MEMBRANE; CELL VACUOLE; CELLULAR DISTRIBUTION; CROSS REACTION; CYTOPLASM; CYTOSOL; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME REGULATION; FRANCISELLA TULARENSIS; GLIOBLASTOMA; GOLGI COMPLEX; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LEGIONELLA PNEUMOPHILA; LEUKEMIA; LYMPHOMA; MOLECULAR RECOGNITION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PALMITOYLATION; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PRENYLATION; PROTEIN PROTEIN INTERACTION; PRURIGO; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; DIMETHYLALLYLTRANSTRANSFERASE; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOPLASMS; PROTEIN PRENYLATION; SUBSTRATE SPECIFICITY;

EID: 84872263809     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2012.10.015     Document Type: Review

References (56)

1. Nguyen U.T., Goody R.S., Alexandrov K. Understanding and exploiting protein prenyltransferases. ChemBioChem 2010, 11:1194-1201.
2. Prior I.A., Hancock J.F. Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol 2012, 23:145-153.
3. Hannoush R.N., Sun J. The chemical toolbox for monitoring protein fatty acylation and prenylation. Nat Chem Biol 2010, 6:498-506.
4. Krzysiak A.J., Aditya A.V., Hougland J.L., Fierke C.A., Gibbs R.A. Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates. Bioorg Med Chem Lett 2010, 20:767-770.
5. Hougland J.L., Lamphear C.L., Scott S.A., Gibbs R.A., Fierke C.A. Context-dependent substrate recognition by protein farnesyltransferase. Biochemistry 2009, 48:1691-1701.
6. Hougland J.L., Hicks K.A., Hartman H.L., Kelly R.A., Watt T.J., Fierke C.A. Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. J Mol Biol 2010, 395:176-190.
7. London N., Lamphear C.L., Hougland J.L., Fierke C.A., Schueler-Furman O. Identification of a novel class of farnesylation targets by structure-based modeling of binding specificity. PLoS Comput Biol 2011, 7:e1002170.
8. Yang Y., Wang B., Ucisik M.N., Cui G., Fierke C.A., Merz K.M. Insights into the mechanistic dichotomy of the protein farnesyltransferase peptide substrates CVIM and CVLS. J Am Chem Soc 2012, 134:820-823.
9. Pais J.E., Bowers K.E., Fierke C.A. Measurement of the alpha-secondary kinetic isotope effect for the reaction catalyzed by mammalian protein farnesyltransferase. J Am Chem Soc 2006, 128:15086-15087.
10. Chan L.N., Hart C., Guo L., Nyberg T., Davies B.S., Fong L.G., Young S.G., Agnew B.J., Tamanoi F. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis 2009, 30:3598-3606.
11. DeGraw A.J., Palsuledesai C., Ochocki J.D., Dozier J.K., Lenevich S., Rashidian M., Distefano M.D. Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation. Chem Biol Drug Des 2010, 76:460-471.
12. Onono F.O., Morgan M.A., Spielmann H.P., Andres D.A., Subramanian T., Ganser A., Reuter C.W. A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics 2010, 9:742-751.
13. Nguyen U.T., Guo Z., Delon C., Wu Y., Deraeve C., Franzel B., Bon R.S., Blankenfeldt W., Goody R.S., Waldmann H., et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat Chem Biol 2009, 5:227-235.
14. Krzysiak A.J., Rawat D.S., Scott S.A., Pais J.E., Handley M., Harrison M.L., Fierke C.A., Gibbs R.A. Combinatorial modulation of protein prenylation. ACS Chem Biol 2007, 2:385-389.
15. Reid T.S., Terry K.L., Casey P.J., Beese L.S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004, 343:417-433.
16. Ahearn I.M., Haigis K., Bar-Sagi D., Philips M.R. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2012, 13:39-51.
17. Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., Fields A.P., Williams C.L. Splice variants of SmgGDS control small GTPase prenylation and membrane localization. J Biol Chem 2010, 285:35255-35266.
18. Hamel B., Monaghan-Benson E., Rojas R.J., Temple B.R., Marston D.J., Burridge K., Sondek J. SmgGDS is a guanine nucleotide exchange factor that specifically activates RhoA and RhoC. J Biol Chem 2011, 286:12141-12148.
19. Bhagatji P., Leventis R., Rich R., Lin C.J., Silvius J.R. Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. Biophys J 2010, 99:3327-3335.
20. Chandra A., Grecco H.E., Pisupati V., Perera D., Cassidy L., Skoulidis F., Ismail S.A., Hedberg C., Hanzal-Bayer M., Venkitaraman A.R., et al. The GDI-like solubilizing factor PDEdelta sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 2012, 14:148-158.
21. Ismail S.A., Chen Y.X., Rusinova A., Chandra A., Bierbaum M., Gremer L., Triola G., Waldmann H., Bastiaens P.I., Wittinghofer A. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat Chem Biol 2011, 7:942-949.
22. Rocks O., Gerauer M., Vartak N., Koch S., Huang Z.P., Pechlivanis M., Kuhlmann J., Brunsveld L., Chandra A., Ellinger B., et al. The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 2010, 141:458-471.
23. Ahearn I.M., Tsai F.D., Court H., Zhou M., Jennings B.C., Ahmed M., Fehrenbacher N., Linder M.E., Philips M.R. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell 2011, 41:173-185.
24. Dekker F.J., Rocks O., Vartak N., Menninger S., Hedberg C., Balamurugan R., Wetzel S., Renner S., Gerauer M., Scholermann B., et al. Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat Chem Biol 2010, 6:449-456.
25. Hanker A.B., Mitin N., Wilder R.S., Henske E.P., Tamanoi F., Cox A.D., Der C.J. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 2010, 29:380-391.
26. Roberts P.J., Mitin N., Keller P.J., Chenette E.J., Madigan J.P., Currin R.O., Cox A.D., Wilson O., Kirschmeier P., Der C.J. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem 2008, 283:25150-25163.
27. Christiansen J.R., Kolandaivelu S., Bergo M.O., Ramamurthy V. RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments. Proc Natl Acad Sci U S A 2011, 108:8862-8866.
28. Wang M., Hossain M.S., Tan W., Coolman B., Zhou J., Liu S., Casey P.J. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth. Oncogene 2010, 29:4959-4970.
29. Majmudar J.D., Hodges-Loaiza H.B., Hahne K., Donelson J.L., Song J., Shrestha L., Harrison M.L., Hrycyna C.A., Gibbs R.A. Amide-modified prenylcysteine based Icmt inhibitors: structure-activity relationships, kinetic analysis and cellular characterization. Bioorg Med Chem 2012, 20:283-295.
30. Go M.L., Leow J.L., Gorla S.K., Schuller A.P., Wang M., Casey P.J. Amino derivatives of indole as potent inhibitors of isoprenylcysteine carboxyl methyltransferase. J Med Chem 2010, 53:6838-6850.
31. Judd W.R., Slattum P.M., Hoang K.C., Bhoite L., Valppu L., Alberts G., Brown B., Roth B., Ostanin K., Huang L., et al. Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT). J Med Chem 2011, 54:5031-5047.
32. Price C.T., Al-Quadan T., Santic M., Jones S.C., Abu Kwaik Y. Exploitation of conserved eukaryotic host cell farnesylation machinery by an F-box effector of Legionella pneumophila. J Exp Med 2010, 207:1713-1726.
33. Ivanov S.S., Charron G., Hang H.C., Roy C.R. Lipidation by the host prenyltransferase machinery facilitates membrane localization of Legionella pneumophila effector proteins. J Biol Chem 2010, 285:34686-34698.
34. Yang W., Yamada M., Tamura Y., Chang K., Mao J., Zou L., Feng Y., Kida K., Scherrer-Crosbie M., Chao W., et al. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther 2011, 339:832-841.
35. Shinozaki S., Inoue Y., Yang W., Fukaya M., Carter E.A., Yu Y.M., Fischman A., Tompkins R., Kaneki M. Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem Biophys Res Commun 2010, 391:1459-1464.
36. Berndt N., Hamilton A.D., Sebti S.M. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011, 11:775-791.
37. Liu M., Sjogren A.K., Karlsson C., Ibrahim M.X., Andersson K.M., Olofsson F.J., Wahlstrom A.M., Dalin M., Yu H., Chen Z., et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci U S A 2010, 107:6471-6476.
38. Sjogren A.K., Andersson K.M., Khan O., Olofsson F.J., Karlsson C., Bergo M.O. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. Leukemia 2011, 25:186-189.
39. Morgan M.A., Onono F.O., Spielmann H.P., Subramanian T., Scherr M., Venturini L., Dallmann I., Ganser A., Reuter C.W. Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells. J Mol Med (Berl) 2012, 90:149-161.
40. Kirschbaum M.H., Synold T., Stein A.S., Tuscano J., Zain J.M., Popplewell L., Karanes C., O'Donnell M.R., Pulone B., Rincon A., et al. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia 2011, 25:1543-1547.
41. Witzig T.E., Tang H., Micallef I.N., Ansell S.M., Link B.K., Inwards D.J., Porrata L.F., Johnston P.B., Colgan J.P., Markovic S.N., et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011, 118:4882-4889.
42. Karp J.E., Vener T.I., Raponi M., Ritchie E.K., Smith B.D., Gore S.D., Morris L.E., Feldman E.J., Greer J.M., Malek S., et al. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood 2012, 119:55-63.
43. Raponi M., Lancet J.E., Fan H., Dossey L., Lee G., Gojo I., Feldman E.J., Gotlib J., Morris L.E., Greenberg P.L., et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008, 111:2589-2596.
44. Rolland D., Ribrag V., Haioun C., Ghesquieres H., Jardin F., Bouabdallah R., Franchi P., Briere J., De Kerviler E., Chassagne-Clement C., et al. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol 2010, 65:781-790.
45. Ding H., Hackbarth J., Schneider P.A., Peterson K.L., Meng X.W., Dai H., Witzig T.E., Kaufmann S.H. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood 2011, 118:4872-4881.
46. Pellicano F., Simara P., Sinclair A., Helgason G.V., Copland M., Grant S., Holyoake T.L. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 2011, 25:1159-1167.
47. Balasis M.E., Forinash K.D., Chen Y.A., Fulp W.J., Coppola D., Hamilton A.D., Cheng J.Q., Sebti S.M. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 2011, 17:2852-2862.
48. Chaponis D., Barnes J.W., Dellagatta J.L., Kesari S., Fast E., Sauvageot C., Panagrahy D., Greene E.R., Ramakrishna N., Wen P.Y., et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol 2011, 104:179-189.
49. Desjardins A., Reardon D.A., Peters K.B., Threatt S., Coan A.D., Herndon J.E., Friedman A.H., Friedman H.S., Vredenburgh J.J. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol 2011, 105:601-606.
50. Haas-Kogan D.A., Banerjee A., Poussaint T.Y., Kocak M., Prados M.D., Geyer J.R., Fouladi M., Broniscer A., Minturn J.E., Pollack I.F., et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 2011, 13:298-306.
51. Barrowman J., Hamblet C., George C.M., Michaelis S. Analysis of prelamin A biogenesis reveals the nucleus to be a CaaX processing compartment. Mol Biol Cell 2008, 19:5398-5408.
52. Yang S.H., Chang S.Y., Andres D.A., Spielmann H.P., Young S.G., Fong L.G. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J Lipid Res 2010, 51:400-405.
53. Kieran M.W., Gordon L., Kleinman M. New approaches to progeria. Pediatrics 2007, 120:834-841.
54. Olive M., Harten I., Mitchell R., Beers J.K., Djabali K., Cao K., Erdos M.R., Blair C., Funke B., Smoot L., et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010, 30:2301-2309.
55. Ragnauth C.D., Warren D.T., Liu Y., McNair R., Tajsic T., Figg N., Shroff R., Skepper J., Shanahan C.M. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010, 121:2200-2210.
56. Liu Z., Meray R.K., Grammatopoulos T.N., Fredenburg R.A., Cookson M.R., Liu Y., Logan T., Lansbury P.T. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A 2009, 106:4635-4640.